NSE: LAURUSLABS | BSE: 540222

Expensive Star

Download real time

625.65 -19.85 (-3.08%)

High volume today

NSE 25 Apr, 2025 3:31 PM (IST)

33,738.3

Market Cap

High in industry

1.3

Beta 1Year

Very High Volatility

Estimates Beat

Laurus Labs' Q4 revenue beats Forecaster estimates by 4%, net profit outperforms estimates by 18.6% See details

Laurus Labs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LAURUSLABS, BSE:540222 Laurus Labs Ltd.

Laurus Labs Ltd.

29 Apr 2024

625.65

-3.08%

Laurus Labs Limited

Neutral: Laurus Labs Ltd.

Recommendation Target

Keynote Capitals Ltd

Quarterly Update Q4FY24

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

29 Apr 2024

625.65

-3.08%

CDMO and Bio to drive profitability

Buy: Laurus Labs Ltd.

Recommendation Target

KRChoksey

Laurus Labs (LAURUSLABS) met our estimates on revenue, EBITDA margins and PAT front for both Q4FY24 and FY24; however, underperformed on GPM in Q4FY24 and marginally underperformed on the same in FY24. Notably, higher value CDMO and custom synthesis segment witnessed 3.5% Y-o-Y (+11.3% Q-o-Q) rise in revenue in Q4FY24 after 4 consecutive quarters of decline seen due to waning of high base effect.

Laurus Labs Ltd. has gained 43.19% in the last 1 Year

Laurus Labs Ltd.

25 Apr 2024

625.65

-3.08%

Product mix and reduced operating leverage hurt profitability

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Labs (LAURUS) delivered better-than-expected revenue in 4QFY24.
However, EBITDA/PAT missed our estimates due to lower sales in the CDMO
segment and weak pricing in the other API segment.

Laurus Labs Ltd. has an average target of 621.00 from 4 brokers.

Laurus Labs Ltd.

29 Jan 2024

625.65

-3.08%

First Light | Bajaj Auto, TVS Motor, SBI Card, Laurus Labs, Cipla, Mahanagar Gas, DCB Bank, SBI Life

Sell: Laurus Labs Ltd.

BOB Capital Markets Ltd.

BJAUT: Healthy revival but priced in; downgrade to SELL. TVSL: On a fast track raise to BUY. SBICARD: Asset quality concerns persist; downgrade to HOLD. LAURUS: Challenges galore cut to SELL. CIPLA: Healthy revenue growth, strong margins. MAHGL: Volume growth accelerating, reiterate BUY. DCBB: NII sequentially flat on high interest cost. SBILIFE: ULIP-led growth; maintains market leadership

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

29 Jan 2024

625.65

-3.08%

Momentum in FDF, Bio and Oncology APIs strong, to aid in growth

Accumulate: Laurus Labs Ltd.

Target

KRChoksey

Laurus Labs’ revenue declined 22.6% Y-o-Y (-2.4% Q-o-Q) to Rs. 11,949 Mn (vs. our estimate of Rs. 12,669, miss of 5.7%) in Q3FY24. The generic API sales declined at 9.2% Y-o-Y (-8.7% Q-o-Q) to Rs. 5,740 Mn (vs. our estimate of Rs. 6,627 Mn, a miss 13.4%) due to high base effect as anticipated with the loss of Paxlovid opportunity in the current period, that took place during Q4FY22-Q3FY23.

Laurus Labs Ltd. has gained 34.32% in the last 6 Months

Laurus Labs Ltd.

25 Jan 2024

625.65

-3.08%

Laurus Labs (SELL): Challenges galore cut to SELL

Sell: Laurus Labs Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Fourth straight quarterly miss with upsets on all fronts; Q3 revenue/ EBITDA well short of Bloomberg consensus by 13%/79%

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

25 Jan 2024

625.65

-3.08%

Operating deleverage drags earnings

Buy: Laurus Labs Ltd.

Motilal Oswal

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

25 Jan 2024

625.65

-3.08%

Laurus Labs Limited

Buy: Laurus Labs Ltd.

Target

Keynote Capitals Ltd

Quarterly Update Q3FY24

Laurus Labs Ltd. has gained 43.19% in the last 1 Year

Laurus Labs Ltd.

01 Dec 2023

625.65

-3.08%

Transforming into a high value non - ARV API and FDF, CDMO synthesis and Bio business

Accumulate: Laurus Labs Ltd.

KRChoksey

Laurus Labs Ltd. (LAURUSLABS) is in the transformation phase by which it intends to reduce the share of ARV (FDF and API) businesses significantly and increase the share of other FDFs and APIs and CDMO synthesis and Biologics businesses. In the meantime, it has incurred over Rs. 26.0 Bn (average 16% of revenue) of capital investments over the last 3 years to augment capacity across generic APIs (non ARVs), FDF (non ARV), CDMO synthesis, and Bio businesses.

Laurus Labs Ltd. is trading at high day volume of 7.1M.

Laurus Labs Ltd.

28 Nov 2023

625.65

-3.08%

Transforming into a high value non ARV API and FDF, CDMO synthesis and Bio business

Accumulate: Laurus Labs Ltd.

KRChoksey

Laurus Labs Ltd. (LAURUSLABS) is in the transformation phase by which it intends to reduce the share of non-ARV (FDF and API) businesses significantly and increase the share of other FDFs and APIs and CDMO synthesis and Biologics businesses. In the meantime, it has incurred over Rs. 26.0 Bn (average 16% of revenue) of capital investments over the last 3 years to augment capacity across generic APIs (non ARVs), FDF (non ARV), CDMO synthesis, and Bio businesses.

Laurus Labs Ltd. has gained 43.19% in the last 1 Year

Is Laurus Labs Ltd. worth buying?

1216 Votes:

Buy 79.61%

Sell 10.86%

Hold 9.54%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Sell SEE REPORTS >

pdf